Home › Cases › Metastatic Spinal Cord Compression — Treatment
Spinal Cord Compression
Metastatic Spinal Cord Compression — Treatment
6 questions
Question 1 · Dexamethasone dose
Correct answer: Dexamethasone 16 mg PO (or equivalent parenteral dose) promptly, then 16 mg/day while awaiting surgery/radiotherapy; reduces cord oedema
Why
NICE NG234: neurological MSCC → dexamethasone 16 mg PO/equivalent parenteral dose promptly, then 16 mg/day while awaiting surgery or RT. Reduces vasogenic cord oedema.
- After surgery or at the start of RT, reduce gradually to stop, guided by response and steroid-withdrawal advice
- PPI protection and blood-glucose monitoring
- If imaging rules out spinal metastases/MSCC, discontinue dexamethasone
- Suspected lymphoma/myeloma without neurology: haematology advice before steroids
- Do not use a traumatic-SCI high-dose methylprednisolone regimen for MSCC
Key point
Neurological MSCC: dexamethasone 16 mg promptly, then 16 mg/day pending surgery/RT. PPI + glucose monitoring; taper after surgery or as RT starts.
Question 2 · Radiotherapy vs surgery
Correct answer: Urgent radiotherapy, within 24 h (usually 8 Gy single fraction)
Why
Oncology/spinal MDT decides. Prostate, breast, SCLC, myeloma and lymphoma are radiosensitive. Surgery unsuitable → RT within 24 h, usually 8 Gy once. Surgery + RT improved walking in selected patients (Patchell). Instability may need stabilisation.
Key point
Surgery unsuitable → RT within 24 h, usually 8 Gy once. MDT decides.
Question 3 · Emergency surgery criteria
Correct answer: Urgent spinal-surgery/oncology assessment for decompression and stabilisation of the unstable fracture; do not rule out recovery from 24 h of paralysis alone
Why
Instability needs urgent spinal surgery + oncology review (SINS 7–12 potentially unstable, 13–18 unstable; refer at ≥7). Paralysis duration alone does not exclude surgery.
Key point
Unstable spine: urgent spinal/oncology review for stabilisation. Refer at SINS ≥7.
Question 4 · Bowel and bladder
Correct answer: Urinary catheterisation for retention. Manual evacuation or suppository for constipation. Neurogenic bowel/bladder management: specialist nurse + continence team
Why
MSCC bowel and bladder dysfunction: urinary retention → painful, risk of overflow incontinence, obstructive uropathy. Insert urethral catheter urgently. Bowel: cord dysfunction causes autonomic failure → constipation, ileus. Neurogenic bladder/bowel: refer to specialist cord injury team for long-term management (intermittent self-catheterisation, bowel programme). Document baseline before treatment.
Key point
MSCC: catheterise for retention. Bowel regime for constipation. Document baseline neurology. Neurogenic bladder/bowel: specialist input.
Question 5 · SINS score
Correct answer: Spinal structural stability: location (junction vertebrae = less stable), pain type, bone lesion (lytic = less stable), spinal alignment, vertebral body involvement, posterolateral involvement
Why
SINS (Spinal Instability Neoplastic Score): 6 components — spinal location (junctional = higher risk), pain (mechanical pain = instability), bone lesion (lytic > mixed > blastic), spinal alignment (subluxation/kyphosis), degree of vertebral body collapse, posterolateral involvement. Total 0-18: 0-6 stable, 7–12 potentially unstable, 13-18 unstable. ≥7 warrants spinal surgical consultation; the score supports, rather than replaces, clinical/imaging assessment.
Key point
SINS 0–6 stable, 7–12 potentially unstable, 13–18 unstable. ≥7 → spinal surgical opinion.
Question 6 · Prognosis and goals of care
Correct answer: Primary cancer prognosis, functional status, extent of systemic disease, time to paralysis, ambulatory status. Short prognosis (<3 months) → focus on symptom control, not aggressive intervention
Why
MSCC goals of care: 30-day mortality 15-30%. Determine: primary cancer and systemic disease extent, prior function, patient's wishes, reversibility of paralysis. Poor prognosis (NSCLC with mets, paraplegia >72h): early palliative care discussion. Good prognosis (myeloma, lymphoma, solitary met): aggressive treatment justifiable. Tools: Tokuhashi score, Tomita score for prognosis.
Key point
MSCC: prognosis depends on primary cancer, systemic disease, time to paralysis. Short prognosis → palliative focus. Tokuhashi/Tomita scoring.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.